Symbols / KROS Stock $11.12 +0.18% Keros Therapeutics, Inc.

Healthcare • Biotechnology • United States • NGM
KROS (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Jasbir S. Seehra Ph.D.
Exch · Country NGM · United States
Market Cap 220.04M
Enterprise Value -51.67M
Income 87.01M
Sales 244.06M
FCF (ttm) 66.24M
Book/sh 15.51
Cash/sh 14.58
Employees 78
Insider 10d —
IPO Apr 08, 2020
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E 4.83
Forward P/E -2.20
PEG —
P/S 0.90
P/B 0.72
P/C —
EV/EBITDA -0.72
EV/Sales -0.21
Quick Ratio 15.10
Current Ratio 15.45
Debt/Eq 5.57
LT Debt/Eq —
EPS (ttm) 2.30
EPS next Y -5.05
EPS Growth —
Revenue Growth -87.30%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-11
Earnings (prior) 2026-03-04
ROA 9.25%
ROE 19.90%
ROIC —
Gross Margin 47.90%
Oper. Margin -75.77%
Profit Margin 35.65%
Shs Outstand 19.79M
Shs Float 19.12M
Insider Own 3.64%
Instit Own 103.43%
Short Float 8.14%
Short Ratio 2.81
Short Interest 1.40M
52W High 22.55
vs 52W High -50.69%
52W Low 10.41
vs 52W Low 6.77%
Beta 0.99
Impl. Vol. 64.84%
Rel Volume 0.54
Avg Volume 412.19K
Volume 221.11K
Target (mean) $22.57
Tgt Median $20.00
Tgt Low $16.00
Tgt High $30.00
# Analysts 7
Recom None
Prev Close $11.10
Price $11.12
Change 0.18%
About

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that arise from ineffective hematopoiesis in Phase 3 clinical trials for Myelodysplastic Syndromes and Phase 2 clinical trials for Myelofibrosis. The company has collaboration and license agreements with Hansoh (Shanghai) Healthtech Co., Ltd. to develop, manufacture, and commercialize elritercept and licensed products containing elritercept; and Takeda Pharmaceuticals U.S.A., Inc. to develop, manufacture, and commercialize elritercept and certain derivative compounds. Keros Therapeutics, Inc. was incorporated in 2015 and is headquartered in Lexington, Massachusetts.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$22.57
Mean price target
2. Current target
$11.12
Latest analyst target
3. DCF / Fair value
$60.25
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$11.12
Low
$16.00
High
$30.00
Mean
$22.57

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-05 main Wells Fargo Overweight → Overweight $20
2025-11-28 main B of A Securities Neutral → Neutral $19
2025-11-12 reit Oppenheimer Outperform → Outperform $27
2025-11-11 main Wells Fargo Overweight → Overweight $23
2025-11-06 main Wedbush Neutral → Neutral $16
2025-08-08 main HC Wainwright & Co. Buy → Buy $20
2025-06-10 down B of A Securities Buy → Neutral $18
2025-05-30 reit Wedbush Neutral → Neutral $15
2025-05-12 main Scotiabank Sector Outperform → Sector Outperform $26
2025-05-08 main HC Wainwright & Co. Buy → Buy $25
2025-04-09 main Truist Securities Buy → Buy $25
2025-04-01 reit Wedbush Neutral → Neutral $15
2025-04-01 reit HC Wainwright & Co. Buy → Buy $40
2025-02-27 main Wells Fargo Overweight → Overweight $26
2025-02-27 main HC Wainwright & Co. Buy → Buy $40
2025-01-21 down Cantor Fitzgerald Overweight → Neutral —
2025-01-17 main Piper Sandler Overweight → Overweight $15
2025-01-17 down Wedbush Outperform → Neutral $15
2025-01-17 reit Guggenheim Neutral → Neutral —
2025-01-16 main Scotiabank Sector Outperform → Sector Outperform $41
News
RSS: Latest KROS news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-15 BIENAIME JEAN-JACQUES Director — 1,000 $11.70 $11,700
2026-04-02 SEEHRA JASBIR Chief Executive Officer — 55,000 $0.30 $16,500
2026-03-09 BIENAIME JEAN-JACQUES Director — 2,000 $11.21 $22,420
2026-03-09 NEWTON CHARLES W. Director — 13,215 $0.00 $0
2026-02-19 SEEHRA JASBIR Chief Executive Officer — 7,015 $16.17 $113,433
2026-02-18 REGNANTE KEITH C Chief Financial Officer — 4,739 $16.35 $77,483
2026-02-18 LERNER LORENA RAQUEL PH.D. Officer — 3,873 $16.35 $63,324
2026-02-18 CHO ESTHER General Counsel — 4,745 $16.35 $77,581
2025-10-15 PONTIFAX MANAGEMENT 4 G.P. 2015, LTD. Beneficial Owner of more than 10% of a Class of Security — 4,787,331 $14.49 $69,368,426
2025-10-15 ADAR1 CAPITAL MANAGEMENT LLC Beneficial Owner of more than 10% of a Class of Security — 5,389,264 $17.75 $95,659,436
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
244.06
+6774.96%
3.55
+2250.99%
0.15
0.00
Operating Revenue
244.06
+6774.96%
3.55
+2250.99%
0.15
0.00
Operating Expense
176.49
-17.20%
213.15
+27.11%
167.69
+55.69%
107.71
Research And Development
129.64
-25.33%
173.63
+28.37%
135.26
+55.00%
87.27
Selling General And Administration
46.85
+14.96%
40.75
+16.99%
34.83
+26.55%
27.52
General And Administrative Expense
46.85
+14.96%
40.75
+16.99%
34.83
+26.55%
27.52
Other Gand A
46.85
+14.96%
40.75
+16.99%
34.83
+26.55%
27.52
Other Operating Expenses
—
-1.24
+48.42%
-2.40
+66.11%
-7.08
Total Expenses
176.49
-17.20%
213.15
+27.11%
167.69
+55.69%
107.71
Operating Income
67.57
+132.24%
-209.59
-25.10%
-167.54
-55.55%
-107.71
Total Operating Income As Reported
67.57
+132.05%
-210.83
-24.06%
-169.94
-48.05%
-114.79
EBITDA
69.08
+133.15%
-208.37
-36.92%
-152.18
-46.32%
-104.00
Normalized EBITDA
44.21
+119.07%
-231.86
-38.90%
-166.93
-55.07%
-107.65
Reconciled Depreciation
1.51
+22.78%
1.23
+50.80%
0.81
+20.92%
0.67
EBIT
67.57
+132.24%
-209.59
-37.00%
-152.99
-46.15%
-104.68
Total Unusual Items
24.87
+5.84%
23.50
+59.24%
14.76
+304.91%
3.64
Total Unusual Items Excluding Goodwill
24.87
+5.84%
23.50
+59.24%
14.76
+304.91%
3.64
Net Income
87.01
+146.44%
-187.35
-22.46%
-152.99
-46.15%
-104.68
Pretax Income
91.90
+149.13%
-187.05
-22.26%
-152.99
-46.15%
-104.68
Net Non Operating Interest Income Expense
—
0.00
0.00
+100.00%
-0.00
Interest Expense Non Operating
—
0.00
0.00
-100.00%
0.00
Net Interest Income
—
0.00
0.00
+100.00%
-0.00
Interest Expense
—
0.00
0.00
-100.00%
0.00
Other Income Expense
24.33
+7.92%
22.54
+54.94%
14.55
+380.01%
3.03
Other Non Operating Income Expenses
-0.54
+43.50%
-0.95
-363.11%
-0.21
+66.39%
-0.61
Gain On Sale Of Security
24.87
+5.84%
23.50
+59.24%
14.76
+304.91%
3.64
Tax Provision
4.88
+1527.67%
0.30
0.00
0.00
Tax Rate For Calcs
0.00
-74.76%
0.00
0.00
0.00
Tax Effect Of Unusual Items
1.32
-73.29%
4.93
0.00
0.00
Net Income Including Noncontrolling Interests
87.01
+146.44%
-187.35
-22.46%
-152.99
-46.15%
-104.68
Net Income From Continuing Operation Net Minority Interest
87.01
+146.44%
-187.35
-22.46%
-152.99
-46.15%
-104.68
Net Income From Continuing And Discontinued Operation
87.01
+146.44%
-187.35
-22.46%
-152.99
-46.15%
-104.68
Net Income Continuous Operations
87.01
+146.44%
-187.35
-22.46%
-152.99
-46.15%
-104.68
Normalized Income
63.46
+130.82%
-205.91
-22.75%
-167.75
-54.86%
-108.32
Net Income Common Stockholders
87.01
+146.44%
-187.35
-22.46%
-152.99
-46.15%
-104.68
Diluted EPS
—
-5.00
+3.85%
-5.20
-25.30%
-4.15
Basic EPS
—
-5.00
+3.85%
-5.20
-25.30%
-4.15
Basic Average Shares
—
37.44
+27.14%
29.45
+25.65%
23.44
Diluted Average Shares
—
37.44
+27.14%
29.45
+25.65%
23.44
Diluted NI Availto Com Stockholders
87.01
+146.44%
-187.35
-22.46%
-152.99
-46.15%
-104.68
Line Item Trend 2025-12-31 2023-12-31
Total Assets
338.02
-8.65%
370.02
Current Assets
315.43
-9.17%
347.29
Cash Cash Equivalents And Short Term Investments
287.42
-13.21%
331.15
Cash And Cash Equivalents
287.42
-13.21%
331.15
Receivables
6.37
+484.05%
1.09
Accounts Receivable
3.57
+2394.41%
0.14
Taxes Receivable
2.25
—
Accrued Interest Receivable
0.56
-41.46%
0.95
Prepaid Assets
19.25
+36.97%
14.05
Other Current Assets
2.40
+139.46%
1.00
Total Non Current Assets
22.59
-0.64%
22.73
Net PPE
21.14
+8.58%
19.47
Gross PPE
25.57
+20.70%
21.19
Accumulated Depreciation
-4.43
-157.85%
-1.72
Properties
—
0.00
Machinery Furniture Equipment
1.30
+125.91%
0.57
Other Properties
24.27
+17.76%
20.61
Leases
—
0.00
Other Non Current Assets
1.45
-55.61%
3.26
Total Liabilities Net Minority Interest
34.89
-7.73%
37.81
Current Liabilities
20.41
-16.24%
24.37
Payables And Accrued Expenses
11.92
-21.38%
15.16
Payables
5.34
-1.94%
5.45
Accounts Payable
1.97
-63.91%
5.45
Current Accrued Expenses
6.58
-32.29%
9.71
Pensionand Other Post Retirement Benefit Plans Current
5.87
-22.17%
7.54
Total Tax Payable
3.38
—
Current Debt And Capital Lease Obligation
2.41
+139.60%
1.00
Current Capital Lease Obligation
2.41
+139.60%
1.00
Other Current Liabilities
0.22
-67.37%
0.67
Total Non Current Liabilities Net Minority Interest
14.47
+7.71%
13.44
Long Term Debt And Capital Lease Obligation
14.47
+7.71%
13.44
Long Term Capital Lease Obligation
14.47
+7.71%
13.44
Stockholders Equity
303.13
-8.75%
332.21
Common Stock Equity
303.13
-8.75%
332.21
Capital Stock
0.00
+33.33%
0.00
Common Stock
0.00
+33.33%
0.00
Preferred Stock
0.00
0.00
Share Issued
40.67
+27.73%
31.84
Ordinary Shares Number
19.54
-38.62%
31.84
Treasury Shares Number
21.13
0.00
Additional Paid In Capital
1,169.45
+63.87%
713.64
Retained Earnings
-481.76
-26.31%
-381.43
Treasury Stock
384.56
—
Total Equity Gross Minority Interest
303.13
-8.75%
332.21
Total Capitalization
303.13
-8.75%
332.21
Working Capital
295.02
-8.64%
322.92
Invested Capital
303.13
-8.75%
332.21
Total Debt
16.88
+16.89%
14.44
Capital Lease Obligations
16.88
+16.89%
14.44
Net Tangible Assets
303.13
-8.75%
332.21
Tangible Book Value
303.13
-8.75%
332.21
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
107.50
+166.83%
-160.87
-29.20%
-124.51
-77.71%
-70.06
Cash Flow From Continuing Operating Activities
107.50
+166.83%
-160.87
-29.20%
-124.51
-77.71%
-70.06
Net Income From Continuing Operations
87.01
+146.44%
-187.35
-22.46%
-152.99
-46.15%
-104.68
Depreciation Amortization Depletion
1.51
+22.78%
1.23
+50.80%
0.81
+20.92%
0.67
Depreciation
1.51
+22.78%
1.23
+50.80%
0.81
+20.92%
0.67
Depreciation And Amortization
1.51
+22.78%
1.23
+50.80%
0.81
+20.92%
0.67
Other Non Cash Items
2.41
+32.42%
1.82
+17.27%
1.55
+64.93%
0.94
Stock Based Compensation
28.70
-17.71%
34.87
+21.24%
28.76
+53.96%
18.68
Operating Gains Losses
-0.01
—
0.00
-66.67%
0.01
Gain Loss On Sale Of PPE
-0.01
0.00
-100.00%
0.00
-66.67%
0.01
Change In Working Capital
-12.11
-5.89%
-11.44
-331.58%
-2.65
-118.52%
14.31
Change In Receivables
-3.08
-18.31%
-2.60
-1717.48%
-0.14
-100.79%
18.00
Changes In Account Receivables
-0.82
+68.26%
-2.60
-1717.48%
-0.14
-100.79%
18.00
Change In Prepaid Assets
4.02
+139.33%
-10.22
-10.05%
-9.28
-179.55%
-3.32
Change In Payables And Accrued Expense
-13.13
-585.83%
2.70
-60.66%
6.87
+39.82%
4.91
Change In Accrued Expense
-10.13
-443.19%
2.95
-43.85%
5.26
-1.22%
5.32
Change In Payable
-3.00
-1105.22%
-0.25
-115.43%
1.61
+495.59%
-0.41
Change In Account Payable
-3.00
-1105.22%
-0.25
-115.43%
1.61
+495.59%
-0.41
Change In Other Working Capital
-1.98
-49.85%
-1.32
-443.75%
0.38
+110.35%
-3.71
Change In Other Current Assets
2.06
+51500.00%
-0.00
+99.16%
-0.48
+69.63%
-1.57
Change In Other Current Liabilities
—
—
0.00
0.00
Investing Cash Flow
-1.55
+19.68%
-1.93
+21.63%
-2.46
-98.55%
-1.24
Cash Flow From Continuing Investing Activities
-1.55
+19.68%
-1.93
+21.63%
-2.46
-98.55%
-1.24
Net PPE Purchase And Sale
-1.55
+19.68%
-1.93
+21.63%
-2.46
-98.55%
-1.24
Purchase Of PPE
-1.55
+19.68%
-1.93
+21.63%
-2.46
-98.55%
-1.24
Capital Expenditure
-1.55
+19.68%
-1.93
+21.63%
-2.46
-98.55%
-1.24
Financing Cash Flow
-378.47
-196.59%
391.82
+118.95%
178.96
+48.75%
120.31
Cash Flow From Continuing Financing Activities
-378.47
-196.59%
391.82
+118.95%
178.96
+48.75%
120.31
Net Common Stock Issuance
-375.00
-198.65%
380.13
+116.20%
175.82
+47.04%
119.58
Common Stock Payments
-375.00
0.00
—
—
Repurchase Of Capital Stock
-375.00
0.00
—
—
Proceeds From Stock Option Exercised
0.29
-97.63%
12.14
+276.47%
3.23
+294.25%
0.82
Net Other Financing Charges
-3.76
-727.75%
-0.45
-382.98%
-0.09
-8.05%
-0.09
Changes In Cash
-272.52
-218.99%
229.02
+340.56%
51.98
+6.08%
49.01
Beginning Cash Position
561.38
+68.91%
332.36
+18.54%
280.38
+21.18%
231.37
End Cash Position
288.86
-48.54%
561.38
+68.91%
332.36
+18.54%
280.38
Free Cash Flow
105.95
+165.08%
-162.80
-28.22%
-126.97
-78.07%
-71.30
Income Tax Paid Supplemental Data
7.14
0.00
—
—
Common Stock Issuance
0.00
-100.00%
380.13
+116.20%
175.82
+47.04%
119.58
Issuance Of Capital Stock
0.00
-100.00%
380.13
+116.20%
175.82
+47.04%
119.58
Net Preferred Stock Issuance
—
—
—
—
Preferred Stock Issuance
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category